Nonalcoholic Fatty Liver Disease: Pathogenesis and Disease Spectrum

Annual Review of Pathology: Mechanisms of Disease

Volumn 11, Issue , 2016, Pages 451-496

  Hardy, Timothy ^a   Oakley, Fiona ^a   Anstee, Quentin M ^a   Day, Christopher P ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

Genetics; NAFLD; NASH; Natural history; Pathophysiology; Steatohepatitis

Indexed keywords

ARTICLE; ENVIRONMENTAL EXPOSURE; HISTOPATHOLOGY; HUMAN; INSULIN RESISTANCE; LIVER CELL CARCINOMA; LIVER DYSFUNCTION; LIVER FAILURE; LIVER FIBROSIS; MICROBIOME; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; PATHOGENESIS; PRIORITY JOURNAL; COMPLICATION; DISEASE COURSE; PATHOPHYSIOLOGY;

DISEASE PROGRESSION; HUMANS; NON-ALCOHOLIC FATTY LIVER DISEASE;

EID: 84971290761     PISSN: 15534006     EISSN: 15534014     Source Type: Book Series    
DOI: 10.1146/annurev-pathol-012615-044224     Document Type: Article

References (305)

1. Anstee QM, McPherson S, Day CP. 2011. How big a problem is non-alcoholic fatty liver disease? Br. Med. J. 343:d3897
2. de Alwis NM, Day CP. 2008. Non-alcoholic fatty liver disease: The mist gradually clears. J. Hepatol. 48(Suppl. 1):S104-12
3. Sanyal AJ, Am. Gastroenterol. Assoc. 2002. AGA technical review on nonalcoholic fatty liver disease. Gastroenterology 123:1705-25
4. Musso G, Gambino R, Cassader M, Pagano G. 2011. Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. Ann. Med. 43:617-49
5. Ekstedt M, Franzen LE, Mathiesen UL, Thorelius L, Holmqvist M, et al. 2006. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 44:865-73
6. Ratziu V, Sheikh MY, Sanyal AJ, Lim JK, Conjeevaram H, et al. 2012. A phase 2, randomized, doubleblind, placebo-controlled study of GS-9450 in subjects with nonalcoholic steatohepatitis. Hepatology 55:419-28
7. Das K, Das K, Mukherjee PS, Ghosh A, Ghosh S, et al. 2010. Nonobese population in a developing country has a high prevalence of nonalcoholic fatty liver and significant liver disease. Hepatology 51:1593-602
8. Baumeister SE, VolzkeH,Marschall P, John U, Schmidt CO, et al. 2008. Impact of fatty liver disease on health care utilization and costs in a general population: A 5-year observation. Gastroenterology 134:85-94
9. Charlton M. 2004. Nonalcoholic fatty liver disease: A review of current understanding and future impact. Clin. Gastroenterol. Hepatol. 2:1048-58
10. Holmberg SD, Spradling PR, Moorman AC, Denniston MM. 2013. Hepatitis C in the United States. N. Engl. J. Med. 368:1859-61
11. Cobbold JF, Anstee QM, Taylor-Robinson SD. 2010. The importance of fatty liver disease in clinical practice. Proc. Nutr. Soc. 69:518-27
12. Ratziu V, Charlotte F, Heurtier A, Gombert S, Giral P, et al. 2005. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology 128:1898-906
13. Argo CK, Caldwell SH. 2009. Epidemiology and natural history of non-alcoholic steatohepatitis. Clin. Liver Dis. 13:511-31
14. Schwenzer NF, Springer F, Schraml C, Stefan N, Machann J, Schick F. 2009. Non-invasive assessment and quantification of liver steatosis by ultrasound, computed tomography and magnetic resonance. J. Hepatol. 51:433-45
15. Thomas EL, Hamilton G, PatelN,O'Dwyer R, Dore CJ, et al. 2005. Hepatic triglyceride content and its relation to body adiposity: A magnetic resonance imaging and proton magnetic resonance spectroscopy study. Gut 54:122-27
16. Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, et al. 2012. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 55:2005-23
17. Saadeh S, Younossi ZM, Remer EM,Gramlich T, Ong JP, et al. 2002. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology 123:745-50
18. Dasarathy S, Dasarathy J, Khiyami A, Joseph R, Lopez R, McCullough AJ. 2009. Validity of real time ultrasound in the diagnosis of hepatic steatosis: A prospective study. J. Hepatol. 51:1061-67
19. Mofrad P, Contos MJ, Haque M, Sargeant C, Fisher RA, et al. 2003. Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology 37:1286-92
20. Vernon G, Baranova A, Younossi ZM. 2011. Systematic review: The epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment. Pharmacol. Ther. 34:274-85
21. Armstrong MJ, Houlihan DD, Bentham L, Shaw JC, Cramb R, et al. 2012. Presence and severity of non-alcoholic fatty liver disease in a large prospective primary care cohort. J. Hepatol. 56:234-40
22. Browning JD, Szczepaniak LS, Dobbins R, Nurenberg P, Horton JD, et al. 2004. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 40:1387-95
23. Szczepaniak LS, Nurenberg P, Leonard D, Browning JD, Reingold JS, et al. 2005. Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population. Am. J. Physiol. Endocrinol. Metab. 288:E462-68
24. Ruhl CE, Everhart JE. 2003. Determinants of the association of overweight with elevated serum alanine aminotransferase activity in the United States. Gastroenterology 124:71-79
25. MinerviniMI, Ruppert K, Fontes P, Volpes R, Vizzini G, et al. 2009. Liver biopsy findings from healthy potential living liver donors: reasons for disqualification, silent diseases and correlation with liver injury tests. J. Hepatol. 50:501-10
26. Nadalin S, Malago M, Valentin-Gamazo C, Testa G, Baba HA, et al. 2005. Preoperative donor liver biopsy for adult living donor liver transplantation: risks and benefits. Liver Transplant. 11:980-86
27. Tran TT, Changsri C, Shackleton CR, Poordad FF, Nissen NN, et al. 2006. Living donor liver transplantation: histological abnormalities found on liver biopsies of apparently healthy potential donors. J. Gastroenterol. Hepatol. 21:381-83
28. Ryan CK, Johnson LA, Germin BI, Marcos A. 2002. One hundred consecutive hepatic biopsies in the workup of living donors for right lobe liver transplantation. Liver Transplant. 8:1114-22
29. Bellentani S, Bedogni G, Miglioli L, Tiribelli C. 2004. The epidemiology of fatty liver. Eur. J. Gastroenterol. Hepatol. 16:1087-93
30. Targher G, Bertolini L, Padovani R, Rodella S, Tessari R, et al. 2007. Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients. Diabetes Care 30:1212-18
31. Jimba S, Nakagami T, Takahashi M, Wakamatsu T, Hirota Y, et al. 2005. Prevalence of non-alcoholic fatty liver disease and its association with impaired glucose metabolism in Japanese adults. Diabet. Med. 22:1141-45
32. Williams CD, Stengel J, Asike MI, TorresDM, Shaw J, et al. 2011. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: A prospective study. Gastroenterology 140:124-31
33. Williamson RM, Price JF, Glancy S, Perry E, Nee LD, et al. 2011. Prevalence of and risk factors for hepatic steatosis and nonalcoholic fatty liver disease in people with type 2 diabetes: The Edinburgh Type 2 Diabetes Study. Diabetes Care 34:1139-44
34. Wanless IR, Lentz JS. 1990. Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors. Hepatology 12:1106-10
35. Silverman JF, Pories WJ, Caro JF. 1989. Liver pathology in diabetes mellitus and morbid obesity. Clinical, pathological, and biochemical considerations. Pathol. Annu. 24(Pt 1):275-302
36. Smith BW, Adams LA. 2011. Nonalcoholic fatty liver disease and diabetes mellitus: pathogenesis and treatment. Nat. Rev. Endocrinol. 7:456-65
37. Wieckowska A, Feldstein AE. 2008. Diagnosis of nonalcoholic fatty liver disease: invasive versus noninvasive. Semin. Liver Dis. 28:386-95
38. Loomba R, Wolfson T, Ang B, Hooker J, Behling C, et al. 2014. Magnetic resonance elastography predicts advanced fibrosis in patients with nonalcoholic fatty liver disease: A prospective study. Hepatology 60:1920-28
39. Banerjee R, Pavlides M, Tunnicliffe EM, Piechnik SK, SaraniaN, et al. 2014. Multiparametric magnetic resonance for the non-invasive diagnosis of liver disease. J. Hepatol. 60:69-77
40. Dyson JK, McPherson S, AnsteeQM. 2013. Non-alcoholic fatty liver disease: non-invasive investigation and risk stratification. J. Clin. Pathol. 66:1033-45
41. Yeh MM, Brunt EM. 2014. Pathological features of fatty liver disease. Gastroenterology 147:754-64
42. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, et al. 2005. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41:1313-21
43. Lackner C,Gogg-Kamerer M, Zatloukal K, Stumptner C, Brunt EM,DenkH. 2008. Ballooned hepatocytes in steatohepatitis: The value of keratin immunohistochemistry for diagnosis. J. Hepatol. 48:821-28
44. Brunt EM, Kleiner DE, Wilson LA, Unalp A, Behling CE, et al. 2009. Portal chronic inflammation in nonalcoholic fatty liver disease (NAFLD): A histologic marker of advanced NAFLD-clinicopathologic correlations from the nonalcoholic steatohepatitis clinical research network. Hepatology 49:809-20
45. Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. 1999. Nonalcoholic steatohepatitis: A proposal for grading and staging the histological lesions. Am. J. Gastroenterol. 94:2467-74
46. Richardson MM, Jonsson JR, Powell EE, Brunt EM, Neuschwander-Tetri BA, et al. 2007. Progressive fibrosis in nonalcoholic steatohepatitis: association with altered regeneration and a ductular reaction. Gastroenterology 133:80-90
47. Brunt EM, Kleiner DE, Wilson LA, Belt P, Neuschwander-Tetri BA, Network NCR. 2011. Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings. Hepatology 53:810-20
48. Younossi ZM, Stepanova M, Rafiq N, Makhlouf H, Younoszai Z, et al. 2011. Pathologic criteria for nonalcoholic steatohepatitis: interprotocol agreement and ability to predict liver-related mortality. Hepatology 53:1874-82
49. Machado M, Marques-Vidal P, Cortez-Pinto H. 2006. Hepatic histology in obese patients undergoing bariatric surgery. J. Hepatol. 45:600-6
50. Bedossa P, Poitou C, Veyrie N, Bouillot JL, Basdevant A, et al. 2012. Histopathological algorithm and scoring system for evaluation of liver lesions in morbidly obese patients. Hepatology 56:1751-59
51. Sanyal AJ, Brunt EM, Kleiner DE, Kowdley KV, Chalasani N, et al. 2011. Endpoints and clinical trial design for nonalcoholic steatohepatitis. Hepatology 54:344-53
52. Bedossa P, FLIP Pathol. Consort. 2014. Utility and appropriateness of the fatty liver inhibition of progression (FLIP) algorithm and steatosis, activity, and fibrosis (SAF) score in the evaluation of biopsies of nonalcoholic fatty liver disease. Hepatology 60:565-75
53. Angulo P. 2013. The natural history of NAFLD. In Non-Alcoholic Fatty Liver Disease: A Practical Guide, ed. GC Farrell, AJ McCulloch, CP Day, pp. 37-45. Oxford, UK: Wiley-Blackwell
54. Pais R, Charlotte F, Fedchuk L, Bedossa P, Lebray P, et al. 2013. A systematic review of follow-up biopsies reveals disease progression in patients with non-alcoholic fatty liver. J. Hepatol. 59:550-56
55. McPherson S, Hardy T, Henderson E, Burt AD, Day CP, Anstee QM. 2015. Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management. J. Hepatol. 62:1148-55
56. Soderberg C, Stal P, Askling J, Glaumann H, Lindberg G, et al. 2010. Decreased survival of subjects with elevated liver function tests during a 28-year follow-up. Hepatology 51:595-602
57. Dam-Larsen S, Becker U, Franzmann MB, Larsen K, Christoffersen P, Bendtsen F. 2009. Final results of a long-term, clinical follow-up in fatty liver patients. Scand. J. Gastroenterol. 44:1236-43
58. Francque S, De Maeght S, AdlerM, Deltenre P, de Galocsy C, et al. 2011. High prevalence of advanced fibrosis in association with the metabolic syndrome in a Belgian prospective cohort of NAFLD patients with elevated ALT. Results of the Belgian NAFLD registry. Acta Gastro-Enterol. Belg. 74:9-16
59. Angulo P, BugianesiE,BjornssonES, CharatcharoenwitthayaP,Mills PR, et al. 2013. Simple noninvasive systems predict long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology 145:782-89.e4
60. Powell EE, Cooksley WG, Hanson R, Searle J, Halliday JW, Powell LW. 1990. The natural history of nonalcoholic steatohepatitis: A follow-up study of forty-two patients for up to 21 years. Hepatology 11:74-80
61. Ratziu V, Giral P, Charlotte F, Bruckert E, Thibault V, et al. 2000. Liver fibrosis in overweight patients. Gastroenterology 118:1117-23
62. Harrison SA, Torgerson S, Hayashi PH. 2003. The natural history of nonalcoholic fatty liver disease: A clinical histopathological study. Am. J. Gastroenterol. 98:2042-47
63. Evans CD, Oien KA, MacSween RN, Mills PR. 2002. Non-alcoholic steatohepatitis: A common cause of progressive chronic liver injury? J. Clin. Pathol. 55:689-92
64. Adams LA, Sanderson S, Lindor KD, Angulo P. 2005. The histological course of nonalcoholic fatty liver disease: A longitudinal study of 103 patients with sequential liver biopsies. J. Hepatol. 42:132-38
65. Lee RG. 1989. Nonalcoholic steatohepatitis: A study of 49 patients. Hum. Pathol. 20:594-98
66. Bacon BR, Farahvash MJ, Janney CG, Neuschwander-Tetri BA. 1994. Nonalcoholic steatohepatitis: an expanded clinical entity. Gastroenterology 107:1103-9
67. Fassio E, Alvarez E, DominguezN, Landeira G, Longo C. 2004. Natural history of nonalcoholic steatohepatitis: A longitudinal study of repeat liver biopsies. Hepatology 40:820-26
68. Singh S, Allen AM, Wang Z, Prokop LJ, MuradMH, Loomba R. 2015. Fibrosis progression in nonalcoholic fatty liver versus nonalcoholic steatohepatitis: A systematic review andmeta-analysis of paired-biopsy studies. Clin. Gastroenterol. Hepatol. 13:643-54.e9
69. Sanyal A, Poklepovic A, Moyneur E, Barghout V. 2010. Population-based risk factors and resource utilization for HCC: US perspective. Curr. Med. Res. Opin. 26:2183-91
70. Parkin DM. 2006. The global health burden of infection-associated cancers in the year 2002. Int. J. Cancer 118:3030-44
71. Starley BQ, Calcagno CJ, Harrison SA. 2010. Nonalcoholic fatty liver disease and hepatocellular carcinoma: A weighty connection. Hepatology 51:1820-32
72. Hashimoto E, Yatsuji S, Tobari M, Taniai M, Torii N, et al. 2009. Hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. J. Gastroenterol. 44(Suppl. 19):89-95
73. Ascha MS, Hanouneh IA, Lopez R, Tamimi TA, Feldstein AF, Zein NN. 2010. The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. Hepatology 51:1972-78
74. Yatsuji S, Hashimoto E. 2006. [Natural history of Japanese patients with non-alcoholic fatty liver disease (NAFLD), especially non-alcoholic steatohepatitis (NASH) patients with hepatocellular carcinoma (HCC)]. Nihon Rinsho. Jpn. J. Clin. Med. 64:1173-79
75. Sanyal AJ, Banas C, Sargeant C, Luketic VA, Sterling RK, et al. 2006. Similarities and differences in outcomes of cirrhosis due to nonalcoholic steatohepatitis and hepatitis C. Hepatology 43:682-89
76. Bhala N, Angulo P, van der Poorten D, Lee E, Hui JM, et al. 2011. The natural history of nonalcoholic fatty liver disease with advanced fibrosis or cirrhosis: an international collaborative study. Hepatology 54:1208-16
77. Hui JM, Kench JG, Chitturi S, Sud A, Farrell GC, et al. 2003. Long-term outcomes of cirrhosis in nonalcoholic steatohepatitis compared with hepatitis C. Hepatology 38:420-27
78. YasuiK,Hashimoto E, TokushigeK,Koike K, Shima T, et al. 2012. Clinical and pathological progression of non-alcoholic steatohepatitis to hepatocellular carcinoma. Hepatol. Res. 42:767-73
79. El-Serag HB, Rudolph KL. 2007. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 132:2557-76
80. Calle EE, RodriguezC,Walker-Thurmond K,ThunMJ. 2003. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N. Engl. J. Med. 348:1625-38
81. Larsson SC, Wolk A. 2007. Overweight, obesity and risk of liver cancer: ameta-analysis of cohort studies. Br. J. Cancer 97:1005-8
82. Nair S, Mason A, Eason J, Loss G, Perrillo RP. 2002. Is obesity an independent risk factor for hepatocellular carcinoma in cirrhosis? Hepatology 36:150-55
83. El-Serag HB, Tran T, Everhart JE. 2004. Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology 126:460-68
84. N'Kontchou G, Paries J, Htar MT, Ganne-Carrie N, Costentin L, et al. 2006. Risk factors for hepatocellular carcinoma in patients with alcoholic or viral C cirrhosis. Clin. Gastroenterol. Hepatol. 4:1062-68
85. Yasui K, Hashimoto E, Komorizono Y, Koike K, Arii S, et al. 2011. Characteristics of patients with nonalcoholic steatohepatitis who develop hepatocellular carcinoma. Clin. Gastroenterol. Hepatol. 9:428-33; quiz e50
86. Dyson J, Jaques B,ChattopadyhayD, Lochan R,Graham J, et al. 2014. Hepatocellular cancer: The impact of obesity, type 2 diabetes and a multidisciplinary team. J. Hepatol. 60:110-17
87. Sanches SC, Ramalho LN, AugustoMJ, da Silva DM, Ramalho FS. 2015. Nonalcoholic steatohepatitis: A search for factual animal models. Biomed. Res. Int. 2015:574832
88. Mayer J, BatesMW, DickieMM.1951. Hereditary diabetes in genetically obese mice. Science 113:746-47
89. Leclercq IA, Field J, Farrell GC. 2003. Leptin-specific mechanisms for impaired liver regeneration in ob/ob mice after toxic injury. Gastroenterology 124:1451-64
90. Chalasani N, Crabb DW, Cummings OW, Kwo PY, Asghar A, et al. 2003. Does leptin play a role in the pathogenesis of human nonalcoholic steatohepatitis? Am. J. Gastroenterol. 98:2771-76
91. Chen H, Charlat O, Tartaglia LA, Woolf EA, Weng X, et al. 1996. Evidence that the diabetes gene encodes the leptin receptor: identification of a mutation in the leptin receptor gene in db/db mice. Cell 84:491-95
92. Maehama T, Dixon JE. 1998. The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J. Biol. Chem. 273:13375-78
93. Horie Y, Suzuki A, Kataoka E, Sasaki T, Hamada K, et al. 2004. Hepatocyte-specific Pten deficiency results in steatohepatitis and hepatocellular carcinomas. J. Clin. Investig. 113:1774-83
94. Tetri LH, Basaranoglu M, Brunt EM, Yerian LM,Neuschwander-Tetri BA. 2008. SevereNAFLD with hepatic necroinflammatory changes in mice fed trans fats and a high-fructose corn syrup equivalent. Am. J. Physiol. Gastrointest. Liver Physiol. 295:G987-95
95. Kohli R, Kirby M, Xanthakos SA, Softic S, Feldstein AE, et al. 2010. High-fructose, medium chain trans fat diet induces liver fibrosis and elevates plasma coenzyme Q9 in a novel murine model of obesity and nonalcoholic steatohepatitis. Hepatology 52:934-44
96. Matsuzawa N, Takamura T, Kurita S, Misu H, Ota T, et al. 2007. Lipid-induced oxidative stress causes steatohepatitis in mice fed an atherogenic diet. Hepatology 46:1392-403
97. Van Rooyen DM, Larter CZ, Haigh WG, Yeh MM, Ioannou G, et al. 2011. Hepatic free cholesterol accumulates in obese, diabetic mice and causes nonalcoholic steatohepatitis. Gastroenterology 141:1393-403, 1403.e1-5
98. Gao D, Wei C, Chen L, Huang J, Yang S, Diehl AM. 2004. Oxidative DNA damage and DNA repair enzyme expression are inversely related in murine models of fatty liver disease. Am. J. Physiol.Gastrointest. Liver Physiol. 287:G1070-77
99. Kirsch R, Clarkson V, Shephard EG, Marais DA, Jaffer MA, et al. 2003. Rodent nutritional model of non-alcoholic steatohepatitis: species, strain and sex difference studies. J. Gastroenterol. Hepatol. 18:1272-82
100. WeltmanMD, Farrell GC, Liddle C. 1996. Increased hepatocyte CYP2E1 expression in a rat nutritional model of hepatic steatosis with inflammation. Gastroenterology 111:1645-53
101. Denda A, KitayamaW, Kishida H, Murata N, Tsutsumi M, et al. 2002. Development of hepatocellular adenomas and carcinomas associated with fibrosis in C57BL/6J male mice given a choline-deficient, L-amino acid-defined diet. Jpn. J. Cancer Res. 93:125-32
102. De Minicis S, Agostinelli L, Rychlicki C, Sorice GP, Saccomanno S, et al. 2014. HCC development is associated to peripheral insulin resistance in a mouse model of NASH. PLOS ONE 9:e97136
103. Anstee QM, Goldin RD. 2006. Mouse models in non-alcoholic fatty liver disease and steatohepatitis research. Int. J. Exp. Pathol. 87:1-16
104. Anstee QM, Targher G, Day CP. 2013. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat. Rev. 10:330-44
105. Samuel VT, Petersen KF, Shulman GI. 2010. Lipid-induced insulin resistance: unravelling the mechanism. Lancet 375:2267-77
106. Anstee QM, Day CP. 2013. The genetics of NAFLD. Nat. Rev. Gastroenterol. Hepatol. 10:645-55
107. Yang L, Li P, Fu S, Calay ES, Hotamisligil GS. 2010. Defective hepatic autophagy in obesity promotes ER stress and causes insulin resistance. Cell Metab. 11:467-78
108. Yamaguchi K, Yang L,McCall S, Huang J, Yu XX, et al. 2007. Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis. Hepatology 45:1366-74
109. MalhiH,Gores GJ, Lemasters JJ. 2006. Apoptosis and necrosis in the liver: A tale of two deaths? Hepatology 43:S31-44
110. Farrell GC, Larter CZ, Hou JY, Zhang RH, Yeh MM, et al. 2009. Apoptosis in experimental NASH is associated with p53 activation and TRAIL receptor expression. J. Gastroenterol. Hepatol. 24:443-52
111. Anstee QM, Concas D, Kudo H, Levene A, Pollard J, et al. 2010. Impact of pan-caspase inhibition in animal models of established steatosis and non-alcoholic steatohepatitis. J. Hepatol. 53:542-50
112. Iredale JP. 2007. Models of liver fibrosis: exploring the dynamic nature of inflammation and repair in a solid organ. J. Clin. Investig. 117:539-48
113. MansbachCMII, Gorelick F. 2007. Development and physiological regulation of intestinal lipid absorption. II. Dietary lipid absorption, complex lipid synthesis, and the intracellular packaging and secretion of chylomicrons. Am. J. Physiol. Gastrointest. Liver Physiol. 293:G645-50
114. Merkel M, Eckel RH, Goldberg IJ. 2002. Lipoprotein lipase: genetics, lipid uptake, and regulation. J. Lipid Res. 43:1997-2006
115. Matherly SC, Puri P. 2012. Mechanisms of simple hepatic steatosis: not so simple after all. Clin. Liver Dis. 16:505-24
116. Cha JY, Repa JJ. 2007. The liver X receptor (LXR) and hepatic lipogenesis. The carbohydrate-response element-binding protein is a target gene of LXR. J. Biol. Chem. 282:743-51
117. Repa JJ, Liang G, Ou J, Bashmakov Y, Lobaccaro JM, et al. 2000. Regulation of mouse sterol regulatory element-binding protein-1c gene (SREBP-1c) by oxysterol receptors, LXRα and LXRβ. Genes Dev. 14:2819-30
118. Mitro N, Mak PA, Vargas L, Godio C, Hampton E, et al. 2007. The nuclear receptor LXR is a glucose sensor. Nature 445:219-23
119. Vacca M, DegirolamoC,Mariani-Costantini R, PalascianoG,Moschetta A. 2011. Lipid-sensing nuclear receptors in the pathophysiology and treatment of the metabolic syndrome. Wiley Interdiscip. Rev. Syst. Biol. Med. 3:562-87
120. Neuschwander-Tetri BA. 2010. Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: The central role of nontriglyceride fatty acid metabolites. Hepatology 52:774-88
121. Sato R, Miyamoto W, Inoue J, TeradaT, Imanaka T, MaedaM. 1999. Sterol regulatory element-binding protein negatively regulates microsomal triglyceride transfer protein gene transcription. J. Biol. Chem. 274:24714-20
122. Berk PD. 2008. Regulatable fatty acid transportmechanisms are central to the pathophysiology of obesity, fatty liver, and metabolic syndrome. Hepatology 48:1362-76
123. Hubbard B, Doege H, Punreddy S, Wu H, Huang X, et al. 2006. Mice deleted for fatty acid transport protein 5 have defective bile acid conjugation and are protected from obesity. Gastroenterology 130:1259-69
124. DoegeH,Grimm D, Falcon A,Tsang B, StormTA, et al. 2008. Silencing of hepatic fatty acid transporter protein 5 in vivo reverses diet-induced non-alcoholic fatty liver disease and improves hyperglycemia. J. Biol. Chem. 283:22186-92
125. Berlanga A, Guiu-Jurado E, Porras JA, Auguet T. 2014. Molecular pathways in non-alcoholic fatty liver disease. Clin. Exp. Gastroenterol. 7:221-39
126. GrecoD,Kotronen A,Westerbacka J, PuigO, Arkkila P, et al. 2008. Gene expression in humanNAFLD. Am. J. Physiol. Gastrointest. Liver Physiol. 294:G1281-87
127. Bechmann LP, Gieseler RK, Sowa JP, Kahraman A, Erhard J, et al. 2010. Apoptosis is associated with CD36/fatty acid translocase upregulation in non-alcoholic steatohepatitis. Liver Int. 30:850-59
128. McGarry JD, BrownNF. 1997. Themitochondrial carnitine palmitoyltransferase system. From concept to molecular analysis. Eur. J. Biochem. 244:1-14
129. Rogue A, Renaud MP, Claude N, Guillouzo A, Spire C. 2011. Comparative gene expression profiles induced by PPARγand PPARα/γagonists in rat hepatocytes. Toxicol. Appl. Pharmacol. 254:18-31
130. Reddy JK. 2001. Nonalcoholic steatosis and steatohepatitis. III. Peroxisomal β-oxidation, PPARα, and steatohepatitis. Am. J. Physiol. Gastrointest. Liver Physiol. 281:G1333-39
131. Nguyen P, Leray V, DiezM, Serisier S, Le Bloc'h J, et al. 2008. Liver lipid metabolism. J. Anim. Physiol. Anim. Nutr. 92:272-83
132. Dentin R, Girard J, Postic C. 2005. Carbohydrate responsive element binding protein (ChREBP) and sterol regulatory element binding protein-1c (SREBP-1c): two key regulators of glucose metabolism and lipid synthesis in liver. Biochimie 87:81-86
133. Donnelly KL, Smith CI, Schwarzenberg SJ, Jessurun J, Boldt MD, Parks EJ. 2005. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J. Clin. Investig. 115:1343-51
134. Dries DR, Gallegos LL, Newton AC. 2007. A single residue in the C1 domain sensitizes novel protein kinase C isoforms to cellular diacylglycerol production. J. Biol. Chem. 282:826-30
135. Samuel VT, Liu ZX, Wang A, Beddow SA, Geisler JG, et al. 2007. Inhibition of protein kinase Cϵ prevents hepatic insulin resistance in nonalcoholic fatty liver disease. J. Clin. Investig. 117:739-45
136. Kumashiro N, Erion DM, Zhang D, Kahn M, Beddow SA, et al. 2011. Cellular mechanism of insulin resistance in nonalcoholic fatty liver disease. PNAS 108:16381-85
137. Fain JN, Bahouth SW, Madan AK. 2004. TNFαrelease by the nonfat cells of human adipose tissue. Int. J. Obes. Relat. Metab. Disord. 28:616-22
138. Sabio G, Das M, Mora A, Zhang Z, Jun JY, et al. 2008. A stress signaling pathway in adipose tissue regulates hepatic insulin resistance. Science 322:1539-43
139. Bruun JM, Lihn AS, Pedersen SB, Richelsen B. 2005. Monocyte chemoattractant protein-1 release is higher in visceral than subcutaneous human adipose tissue (AT): implication of macrophages resident in the AT. J. Clin. Endocrinol. Metab. 90:2282-89
140. Yamauchi T, Hara K, Kubota N, Terauchi Y, Tobe K, et al. 2003. Dual roles of adiponectin/Acrp30 in vivo as an anti-diabetic and anti-atherogenic adipokine. Curr. Drug Targets Immune Endocr. Metab. Disord. 3:243-54
141. Kadowaki T, Yamauchi T, Kubota N, Hara K, Ueki K, Tobe K. 2006. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J. Clin. Investig. 116:1784-92
142. Xu A, Wang Y, Keshaw H, Xu LY, Lam KS, Cooper GJ. 2003. The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. J. Clin. Investig. 112:91-100
143. Matsubara M. 2004. Plasma adiponectin decrease in women with nonalcoholic fatty liver. Endocr. J. 51:587-93
144. Andreelli F, Foretz M, Knauf C, Cani PD, Perrin C, et al. 2006. Liver adenosine monophosphateactivated kinase-α2 catalytic subunit is a key target for the control of hepatic glucose production by adiponectin and leptin but not insulin. Endocrinology 147:2432-41
145. Rabe K, Lehrke M, Parhofer KG, BroedlUC. 2008. Adipokines and insulin resistance. Mol. Med. 14:741-51
146. Myers MG, Cowley MA, Munzberg H. 2008. Mechanisms of leptin action and leptin resistance. Annu. Rev. Physiol. 70:537-56
147. Seol W, Choi HS, Moore DD. 1995. Isolation of proteins that interact specifically with the retinoid X receptor: two novel orphan receptors. Mol. Endocrinol. 9:72-85
148. Forman BM, Goode E, Chen J, Oro AE, Bradley DJ, et al. 1995. Identification of a nuclear receptor that is activated by farnesol metabolites. Cell 81:687-93
149. Caron S, Huaman SamanezC,Dehondt H, Ploton M, BriandO, et al. 2013. FarnesoidXreceptor inhibits the transcriptional activity of carbohydrate response element binding protein in human hepatocytes. Mol. Cell. Biol. 33:2202-11
150. Lefebvre P, Cariou B, Lien F, Kuipers F, Staels B. 2009. Role of bile acids and bile acid receptors in metabolic regulation. Physiol. Rev. 89:147-91
151. Pineda Torra I, Claudel T, Duval C, Kosykh V, Fruchart JC, Staels B. 2003. Bile acids induce the expression of the human peroxisome proliferator-activated receptorαgene via activation of the farnesoid X receptor. Mol. Endocrinol. 17:259-72
152. Claudel T, Inoue Y, BarbierO,Duran-Sandoval D, Kosykh V, et al. 2003. Farnesoid X receptor agonists suppress hepatic apolipoprotein CIII expression. Gastroenterology 125:544-55
153. Lefebvre P, Staels B. 2014. Failing FXR expression in the liver links aging to hepatic steatosis. J. Hepatol. 60:689-90
154. Anstee QM, Daly AK, Day CP. 2011. Genetic modifiers of non-alcoholic fatty liver disease progression. Biochim. Biophys. Acta 1812:1557-66
155. Li ZZ, Berk M, McIntyre TM, Feldstein AE. 2009. Hepatic lipid partitioning and liver damage in nonalcoholic fatty liver disease: role of stearoyl-CoA desaturase. J. Biol. Chem. 284:5637-44
156. Mari M, Caballero F, Colell A, Morales A, Caballeria J, et al. 2006. Mitochondrial free cholesterol loading sensitizes to TNF-and Fas-mediated steatohepatitis. Cell Metab. 4:185-98
157. Puri P, Baillie RA,Wiest MM, Mirshahi F, Choudhury J, et al. 2007. A lipidomic analysis of nonalcoholic fatty liver disease. Hepatology 46:1081-90
158. Robertson G, Leclercq I, Farrell GC. 2001. Nonalcoholic steatosis and steatohepatitis. II. Cytochrome P-450 enzymes and oxidative stress. Am. J. Physiol. Gastrointest. Liver Physiol. 281:G1135-39
159. Dentin R. 2006. Liver-specific inhibition of ChREBP improves hepatic steatosis and insulin resistance in ob/ob mice. Diabetes 55:2159-70
160. Sanyal AJ, Campbell-Sargent C, Mirshahi F, Rizzo WB, Contos MJ, et al. 2001. Nonalcoholic steatohepatitis: association of insulin resistance andmitochondrial abnormalities. Gastroenterology 120:1183-92
161. George J, Pera N, Phung N, Leclercq I, Yun Hou J, Farrell G. 2003. Lipid peroxidation, stellate cell activation and hepatic fibrogenesis in a rat model of chronic steatohepatitis. J. Hepatol. 39:756-64
162. Todd DJ, Lee AH, Glimcher LH. 2008. The endoplasmic reticulum stress response in immunity and autoimmunity. Nat. Rev. Immunol. 8:663-74
163. Puri P, Mirshahi F, Cheung O, Natarajan R,Maher JW, et al. 2008. Activation and dysregulation of the unfolded protein response in nonalcoholic fatty liver disease. Gastroenterology 134:568-76
164. Tilg H, Moschen AR. 2010. Evolution of inflammation in nonalcoholic fatty liver disease: The multiple parallel hits hypothesis. Hepatology 52:1836-46
165. Hotamisligil GS. 2010. Endoplasmic reticulum stress and the inflammatory basis of metabolic disease. Cell 140:900-17
166. WeiY,WangD,Topczewski F, Pagliassotti MJ. 2006. Saturated fatty acids induce endoplasmic reticulum stress and apoptosis independently of ceramide in liver cells. Am. J. Physiol. Endocrinol. Metab. 291:E275-81
167. Wei Y,Wang D, Pagliassotti MJ. 2007. Saturated fatty acid-mediated endoplasmic reticulum stress and apoptosis are augmented by trans-10, cis-12-conjugated linoleic acid in liver cells. Mol. Cell. Biochem. 303:105-13
168. Medzhitov R. 2001. Toll-like receptors and innate immunity. Nat. Rev. Immunol. 1:135-45
169. Rivera CA, Adegboyega P, van RooijenN,Tagalicud A, Allman M, Wallace M. 2007. Toll-like receptor-4 signaling and Kupffer cells play pivotal roles in the pathogenesis of non-alcoholic steatohepatitis. J. Hepatol. 47:571-79
170. Cani PD, Amar J, Iglesias MA, Poggi M, Knauf C, et al. 2007. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes 56:1761-72
171. Yang SQ, Lin HZ, Lane MD, Clemens M, Diehl AM. 1997. Obesity increases sensitivity to endotoxin liver injury: implications for the pathogenesis of steatohepatitis. PNAS 94:2557-62
172. Hritz I, Mandrekar P, Velayudham A, Catalano D, Dolganiuc A, et al. 2008. The critical role of tolllike receptor (TLR) 4 in alcoholic liver disease is independent of the common TLR adapter MyD88. Hepatology 48:1224-31
173. Miura K, Kodama Y, Inokuchi S, Schnabl B, Aoyama T, et al. 2010. Toll-like receptor 9 promotes steatohepatitis by induction of interleukin-1βin mice. Gastroenterology 139:323-34.e7
174. Petrasek J, Dolganiuc A, Csak T, Kurt-Jones EA, Szabo G. 2011. Type I interferons protect from Tolllike receptor 9-associated liver injury and regulate IL-1 receptor antagonist in mice. Gastroenterology 140:697-708.e4
175. MiuraK, YangL, van RooijenN, Brenner DA, OhnishiH, Seki E. 2013. Toll-like receptor 2 and palmitic acid cooperatively contribute to the development of nonalcoholic steatohepatitis through inflammasome activation in mice. Hepatology 57:577-89
176. Rivera CA, Gaskin L, Allman M, Pang J, Brady K, et al. 2010. Toll-like receptor-2 deficiency enhances non-alcoholic steatohepatitis. BMC Gastroenterol. 10:52
177. Feldstein AE, Canbay A, Angulo P, Taniai M, Burgart LJ, et al. 2003. Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis. Gastroenterology 125:437-43
178. Malhi H, Barreyro FJ, Isomoto H, Bronk SF, Gores GJ. 2007. Free fatty acids sensitise hepatocytes to TRAIL mediated cytotoxicity. Gut 56:1124-31
179. Crespo J, Cayon A, Fernandez-Gil P, Hernandez-Guerra M, Mayorga M, et al. 2001. Gene expression of tumor necrosis factor αand TNF-receptors, p55 and p75, in nonalcoholic steatohepatitis patients. Hepatology 34:1158-63
180. McClain CJ, Barve S, Deaciuc I. 2007. Good fat/bad fat. Hepatology 45:1343-46
181. Feldstein AE, WerneburgNW,CanbayA,Guicciardi ME,Bronk SF, et al. 2004. Free fatty acids promote hepatic lipotoxicity by stimulating TNF-αexpression via a lysosomal pathway. Hepatology 40:185-94
182. Li Z, Berk M, McIntyre TM, Gores GJ, Feldstein AE. 2008. The lysosomal-mitochondrial axis in free fatty acid-induced hepatic lipotoxicity. Hepatology 47:1495-503
183. Feldstein AE, Werneburg NW, Li Z, Bronk SF, Gores GJ. 2006. Bax inhibition protects against free fatty acid-induced lysosomal permeabilization. Am. J. Physiol. Gastrointest. Liver Physiol. 290:G1339-46
184. Wieckowska A, ZeinNN,Yerian LM,LopezAR, McCullough AJ, Feldstein AE. 2006. In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease. Hepatology 44:27-33
185. Witek RP, Stone WC, Karaca FG, Syn WK, Pereira TA, et al. 2009. Pan-caspase inhibitor VX-166 reduces fibrosis in an animal model of nonalcoholic steatohepatitis. Hepatology 50:1421-30
186. Malhi H, Guicciardi ME, Gores GJ. 2010. Hepatocyte death: A clear and present danger. Physiol. Rev. 90:1165-94
187. Gautheron J, Vucur M, Reisinger F, Cardenas DV, Roderburg C, et al. 2014. A positive feedback loop between RIP3 and JNK controls non-alcoholic steatohepatitis. EMBO Mol. Med. 6:1062-74
188. Petrasek J, Bala S, Csak T, Lippai D, Kodys K, et al. 2012. IL-1 receptor antagonist ameliorates inflammasome-dependent alcoholic steatohepatitis in mice. J. Clin. Investig. 122:3476-89
189. Wree A, EguchiA,McGeoughMD, Pena CA, Johnson CD, et al. 2014.NLRP3inflammasome activation results in hepatocyte pyroptosis, liver inflammation, and fibrosis in mice. Hepatology 59:898-910
190. Amir M, Czaja MJ. 2011. Autophagy in nonalcoholic steatohepatitis. Expert Rev. Gastroenterol. Hepatol. 5:159-66
191. Singh R, Kaushik S, Wang Y, Xiang Y, Novak I, et al. 2009. Autophagy regulates lipid metabolism. Nature 458:1131-35
192. Kim I, Rodriguez-Enriquez S, Lemasters JJ. 2007. Selective degradation of mitochondria by mitophagy. Arch. Biochem. Biophys. 462:245-53
193. Mei S, Ni HM, Manley S, Bockus A, Kassel KM, et al. 2011. Differential roles of unsaturated and saturated fatty acids on autophagy and apoptosis in hepatocytes. J. Pharmacol. Exp. Ther. 339:487-98
194. Hernandez-Gea V, Friedman SL. 2011. Pathogenesis of liver fibrosis. Annu. Rev. Pathol. 6:425-56
195. Lomonaco R, Ortiz-Lopez C, Orsak B, Webb A, Hardies J, et al. 2012. Effect of adipose tissue insulin resistance on metabolic parameters and liver histology in obese patients with nonalcoholic fatty liver disease. Hepatology 55:1389-97
196. Leclercq IA, Farrell GC, Schriemer R, RobertsonGR. 2002. Leptin is essential for the hepatic fibrogenic response to chronic liver injury. J. Hepatol. 37:206-13
197. Marra F. 2007. Leptin and liver tissue repair:Do rodent models provide the answers? J. Hepatol. 46:12-18
198. Jiang JX, Mikami K, Shah VH, Torok NJ. 2008. Leptin induces phagocytosis of apoptotic bodies by hepatic stellate cells via a Rho guanosine triphosphatase-dependent mechanism. Hepatology 48:1497-505
199. Ding X, Saxena NK, Lin S, Xu A, Srinivasan S, Anania FA. 2005. The roles of leptin and adiponectin: A novel paradigm in adipocytokine regulation of liver fibrosis and stellate cell biology. Am. J. Pathol. 166:1655-69
200. Wang J, Leclercq I, Brymora JM, Xu N, Ramezani-Moghadam M, et al. 2009. Kupffer cells mediate leptin-induced liver fibrosis. Gastroenterology 137:713-23
201. Kamada Y, Tamura S, Kiso S,Matsumoto H, Saji Y, et al. 2003. Enhanced carbon tetrachloride-induced liver fibrosis in mice lacking adiponectin. Gastroenterology 125:1796-807
202. Caligiuri A, BertolaniC,Guerra CT,Aleffi S, Galastri S, et al. 2008. Adenosinemonophosphate-activated protein kinase modulates the activated phenotype of hepatic stellate cells. Hepatology 47:668-76
203. Lanthier N, Horsmans Y, Leclercq IA. 2009. The metabolic syndrome: how it may influence hepatic stellate cell activation and hepatic fibrosis. Curr. Opin. Clin. Nutr. Metab. Care 12:404-11
204. Oakley F, Teoh V, Ching ASG, Bataller R, Colmenero J, et al. 2009. Angiotensin II activates I kappaB kinase phosphorylation of RelA at Ser 536 to promote myofibroblast survival and liver fibrosis. Gastroenterology 136:2334-44.e1
205. Paradis V, PerlemuterG, Bonvoust F,Dargere D, Parfait B, et al. 2001. High glucose and hyperinsulinemia stimulate connective tissue growth factor expression: A potential mechanism involved in progression to fibrosis in nonalcoholic steatohepatitis. Hepatology 34:738-44
206. Miyahara T, Schrum L, Rippe R, Xiong S, Yee HF Jr., et al. 2000. Peroxisome proliferator-activated receptors and hepatic stellate cell activation. J. Biol. Chem. 275:35715-22
207. Marra F, Efsen E, Romanelli RG, Caligiuri A, Pastacaldi S, et al. 2000. Ligands of peroxisome proliferator-activated receptorγmodulate profibrogenic and proinflammatory actions in hepatic stellate cells. Gastroenterology 119:466-78
208. Moran-Salvador E, Titos E, Rius B, Gonzalez-Periz A, Garcia-Alonso V, et al. 2013. Cell-specific PPARγdeficiency establishes anti-inflammatory and anti-fibrogenic properties for this nuclear receptor in non-parenchymal liver cells. J. Hepatol. 59:1045-53
209. Staels B, Rubenstrunk A, Noel B, Rigou G, Delataille P, et al. 2013. Hepatoprotective effects of the dual peroxisome proliferator-activated receptor alpha/delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. Hepatology 58:1941-52
210. Wagner M, Zollner G, TraunerM. 2008. Nuclear bile acid receptor farnesoid X receptor meets nuclear factor-kappaB: new insights into hepatic inflammation. Hepatology 48:1383-86
211. Wang YD, Chen WD,WangM, YuD, Forman BM, HuangW. 2008. Farnesoid X receptor antagonizes nuclear factor kappaB in hepatic inflammatory response. Hepatology 48:1632-43
212. Zhang S, Wang J, Liu Q, Harnish DC. 2009. Farnesoid X receptor agonist WAY-362450 attenuates liver inflammation and fibrosis in murine model of non-alcoholic steatohepatitis. J. Hepatol. 51:380-88
213. Mudaliar S, Henry RR, Sanyal AJ, Morrow L, Marschall HU, et al. 2013. Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease. Gastroenterology 145:574-82.e1
214. Tomita K, Teratani T, Suzuki T, Shimizu M, Sato H, et al. 2014. Free cholesterol accumulation in hepatic stellate cells: mechanism of liver fibrosis aggravation in nonalcoholic steatohepatitis in mice. Hepatology 59:154-69
215. Van Rooyen DM, Gan LT, Yeh MM, HaighWG, Larter CZ, et al. 2013. Pharmacological cholesterol lowering reverses fibrotic NASH in obese, diabetic mice with metabolic syndrome. J. Hepatol. 59:144-52
216. Teixeira-Clerc F, Julien B, Grenard P, Tran Van Nhieu J, Deveaux V, et al. 2006. CB1 cannabinoid receptor antagonism: A new strategy for the treatment of liver fibrosis. Nat. Med. 12:671-76
217. Julien B, Grenard P, Teixeira-Clerc F, Van Nhieu JT, Li L, et al. 2005. Antifibrogenic role of the cannabinoid receptor CB2 in the liver. Gastroenterology 128:742-55
218. Campisi J, d'Adda di Fagagna F. 2007. Cellular senescence: when bad things happen to good cells. Nat. Rev. Mol. Cell Biol. 8:729-40
219. Jeyapalan JC, Ferreira M, Sedivy JM, Herbig U. 2007. Accumulation of senescent cells in mitotic tissue of aging primates. Mech. Ageing Dev. 128:36-44
220. Tchkonia T, Morbeck DE, Von Zglinicki T, Van Deursen J, Lustgarten J, et al. 2010. Fat tissue, aging, and cellular senescence. Aging Cell 9:667-84
221. Weyemi U, Lagente-Chevallier O, Boufraqech M, Prenois F, Courtin F, et al. 2012. ROS-generating NADPHoxidaseNOX4is a critical mediator in oncogenic H-Ras-inducedDNAdamage and subsequent senescence. Oncogene 31:1117-29
222. Burton DG. 2009. Cellular senescence, ageing and disease. Age 31:1-9
223. Krizhanovsky V, Yon M, Dickins RA, Hearn S, Simon J, et al. 2008. Senescence of activated stellate cells limits liver fibrosis. Cell 134:657-67
224. Aravinthan A, Scarpini C, Tachtatzis P, Verma S, Penrhyn-Lowe S, et al. 2013. Hepatocyte senescence predicts progression in non-alcohol-related fatty liver disease. J. Hepatol. 58:549-56
225. Choi SS, Omenetti A, Witek RP, Moylan CA, Syn WK, et al. 2009. Hedgehog pathway activation and epithelial-to-mesenchymal transitions during myofibroblastic transformation of rat hepatic cells in culture and cirrhosis. Am. J. Physiol. Gastrointest. Liver Physiol. 297:G1093-106
226. Choi SS, Omenetti A, Syn WK, Diehl AM. 2011. The role of Hedgehog signaling in fibrogenic liver repair. Int. J. Biochem. Cell Biol. 43:238-44
227. Syn WK, Jung Y, Omenetti A, Abdelmalek M, Guy CD, et al. 2009. Hedgehog-mediated epithelialto-mesenchymal transition and fibrogenic repair in nonalcoholic fatty liver disease. Gastroenterology 137:1478-88.e8
228. Hernandez-Gea V, Ghiassi-Nejad Z, Rozenfeld R, Gordon R, Fiel MI, et al. 2012. Autophagy releases lipid that promotes fibrogenesis by activated hepatic stellate cells in mice and in human tissues. Gastroenterology 142:938-46
229. Miura K, Yang L, van Rooijen N, Ohnishi H, Seki E. 2012. Hepatic recruitment of macrophages promotes nonalcoholic steatohepatitis through CCR2. Am. J. Physiol. Gastrointest. Liver Physiol. 302:G1310-21
230. Baeck C, Wehr A, Karlmark KR, Heymann F, Vucur M, et al. 2012. Pharmacological inhibition of the chemokine CCL2 (MCP-1) diminishes liver macrophage infiltration and steatohepatitis in chronic hepatic injury. Gut 61:416-26
231. Baeck C, Wei X, Bartneck M, Fech V, Heymann F, et al. 2014. Pharmacological inhibition of the chemokineC-C motif chemokine ligand 2 (monocyte chemoattractant protein 1) accelerates liver fibrosis regression by suppressing Ly-6C+ macrophage infiltration in mice. Hepatology 59:1060-72
232. Hirschhorn JN, Daly MJ. 2005. Genome-wide association studies for common diseases and complex traits. Nat. Rev. Genet. 6:95-108
233. Schwimmer JB, Celedon MA, Lavine JE, Salem R, Campbell N, et al. 2009. Heritability of nonalcoholic fatty liver disease. Gastroenterology 136:1585-92
234. Makkonen J, Pietilainen KH, Rissanen A, Kaprio J, Yki-Jarvinen H. 2009. Genetic factors contribute to variation in serum alanine aminotransferase activity independent of obesity and alcohol: A study in monozygotic and dizygotic twins. J. Hepatol. 50:1035-42
235. Bambha K, Belt P, Abraham M,Wilson LA, Pabst M, et al. 2012. Ethnicity and nonalcoholic fatty liver disease. Hepatology 55:769-80
236. Wang WY, Barratt BJ, Clayton DG, Todd JA. 2005. Genome-wide association studies: theoretical and practical concerns. Nat. Rev. Genet. 6:109-18
237. Romeo S, Kozlitina J, Xing C, Pertsemlidis A, Cox D, et al. 2008. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat. Genet. 40:1461-65
238. Yuan X, WaterworthD,Perry JR,Lim N, Song K, et al. 2008. Population-based genome-wide association studies reveal six loci influencing plasma levels of liver enzymes. Am. J. Hum. Genet. 83:520-28
239. Speliotes EK, Yerges-Armstrong LM,Wu J, Hernaez R, Kim LJ, et al. 2011. Genome-wide association analysis identifies variants associated with nonalcoholic fatty liver disease that have distinct effects on metabolic traits. PLOS Genet. 7:e1001324
240. Chambers JC, Zhang W, Sehmi J, Li X,WassMN, et al. 2011. Genome-wide association study identifies loci influencing concentrations of liver enzymes in plasma. Nat. Genet. 43:1131-38
241. Feitosa MF, Wojczynski MK, North KE, Zhang Q, Province MA, et al. 2013. The ERLIN1-CHUKCWF19L1 gene cluster influences liver fat deposition and hepatic inflammation in the NHLBI Family Heart Study. Atherosclerosis 228:175-80
242. Valenti L, Al-Serri A, Daly AK, Galmozzi E, Rametta R, et al. 2010. Homozygosity for the patatin-like phospholipase-3/adiponutrin I148M polymorphism influences liver fibrosis in patientswith nonalcoholic fatty liver disease. Hepatology 51:1209-17
243. Rotman Y, Koh C, Zmuda JM, Kleiner DE, Liang TJ, Nash CRN. 2010. The association of genetic variability in patatin-like phospholipase domain-containing protein 3 (PNPLA3) with histological severity of nonalcoholic fatty liver disease. Hepatology 52:894-903
244. Kollerits B, Coassin S, Kiechl S,Hunt SC, Paulweber B, et al. 2010. A common variant in the adiponutrin gene influences liver enzyme values. J. Med. Genet. 47:116-19
245. Liu YL, Patman GL, Leathart JB, Piguet AC, Burt AD, et al. 2014. Carriage of the PNPLA3 rs738409 C > G polymorphism confers an increased risk of non-alcoholic fatty liver disease associated hepatocellular carcinoma. J. Hepatol. 61:75-81
246. Zimmermann R, Strauss JG, Haemmerle G, Schoiswohl G, Birner-Gruenberger R, et al. 2004. Fat mobilization in adipose tissue is promoted by adipose triglyceride lipase. Science 306:1383-86
247. Rydel TJ, Williams JM, Krieger E, Moshiri F, Stallings WC, et al. 2003. The crystal structure, mutagenesis, and activity studies reveal that patatin is a lipid acyl hydrolase with a Ser-Asp catalytic dyad. Biochemistry 42:6696-708
248. He S, McPhaul C, Li JZ, Garuti R, Kinch L, et al. 2010. A sequence variation (I148M) in PNPLA3 associated with nonalcoholic fatty liver disease disrupts triglyceride hydrolysis. J. Biol. Chem. 285:6706-15
249. Romeo S, Sentinelli F, Dash S, Yeo GS, Savage DB, et al. 2010. Morbid obesity exposes the association between PNPLA3 I148M (rs738409) and indices of hepatic injury in individuals of European descent. Int. J. Obes. 34:190-94
250. Pirazzi C, Adiels M, BurzaMA, Mancina RM, LevinM, et al. 2012. Patatin-like phospholipase domaincontaining 3 (PNPLA3) I148M (rs738409) affects hepatic VLDL secretion in humans and in vitro. J. Hepatol. 57:1276-82
251. Lake AC, Sun Y, Li JL, Kim JE, Johnson JW, et al. 2005. Expression, regulation, and triglyceride hydrolase activity of Adiponutrin family members. J. Lipid Res. 46:2477-87
252. Wilson PA, Gardner SD, Lambie NM, Commans SA, Crowther DJ. 2006. Characterization of the human patatin-like phospholipase family. J. Lipid Res. 47:1940-49
253. Kotronen A, Johansson LE, Johansson LM, Roos C, Westerbacka J, et al. 2009. A common variant in PNPLA3, which encodes adiponutrin, is associated with liver fat content in humans. Diabetologia 52:1056-60
254. Huang Y, He S, Li JZ, Seo YK, Osborne TF, et al. 2010. A feed-forward loop amplifies nutritional regulation of PNPLA3. PNAS 107:7892-97
255. Chen W, Chang B, Li L, Chan L. 2010. Patatin-like phospholipase domain-containing 3/adiponutrin deficiency in mice is not associated with fatty liver disease. Hepatology 52:1134-42
256. Li JZ, Huang Y, Karaman R, Ivanova PT, Brown HA, et al. 2012. Chronic overexpression of PNPLA3I148M in mouse liver causes hepatic steatosis. J. Clin. Investig. 122:4130-44
257. BasantaniMK, Sitnick MT, Cai L, BrennerDS, GardnerNP, et al. 2011. Pnpla3/Adiponutrin deficiency in mice does not contribute to fatty liver disease or metabolic syndrome. J. Lipid Res. 52(2):318-29
258. Perttilä J, Huaman-Samanez C, Caron S, Tanhuanpää K, Staels B, et al. 2012. PNPLA3 is regulated by glucose in human hepatocytes, and its I148M mutant slows down triglyceride hydrolysis. Am. J. Physiol. Endocrinol. Metab. 302(9):E1063-69
259. Kumari M, Schoiswohl G, Chitraju C, Paar M, Cornaciu I, et al. 2012. Adiponutrin functions as a nutritionally regulated lysophosphatidic acid acyltransferase. Cell Metab. 15(5):691-702
260. Pirazzi C, Valenti L, Motta BM, Pingitore P, Hedfalk K, et al. 2014. PNPLA3 has retinyl-palmitate lipase activity in human hepatic stellate cells. Hum. Mol. Genet. 23:4077-85
261. Jha P, ClaudelT, Baghdasaryan A,MuellerM,Halilbasic E, et al. 2014. Role of adipose triglyceride lipase (PNPLA2) in protection from hepatic inflammation in mousemodels of steatohepatitis and endotoxemia. Hepatology 59:858-69
262. Beer NL,TribbleND, McCulloch LJ, Roos C, Johnson PR, et al. 2009. The P446L variant inGCKRassociated with fasting plasma glucose and triglyceride levels exerts its effect through increased glucokinase activity in liver. Hum. Mol. Genet. 18:4081-88
263. Valenti L, Alisi A, Nobili V. 2012. Unraveling the genetics of fatty liver in obese children: additive effect of P446L GCKR and I148M PNPLA3 polymorphisms. Hepatology 55:661-63
264. Palmer ND, Musani SK, Yerges-Armstrong LM, Feitosa MF, Bielak LF, et al. 2013. Characterization of European ancestry nonalcoholic fatty liver disease-associated variants in individuals of African and Hispanic descent. Hepatology 58:966-75
265. Kozlitina J, Smagris E, Stender S, Nordestgaard BG, Zhou HH, et al. 2014. Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease. Nat. Genet. 46:352-56
266. Holmen OL, Zhang H, Fan Y, Hovelson DH, Schmidt EM, et al. 2014. Systematic evaluation of coding variation identifies a candidate causal variant in TM6SF2 influencing total cholesterol and myocardial infarction risk. Nat. Genet. 46:345-51
267. Liu YL, Reeves HL, Burt AD, Tiniakos D, McPherson S, et al. 2014. TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease. Nat. Commun. 5:4309
268. Dongiovanni P, Petta S, Maglio C, Fracanzani AL, Pipitone R, et al. 2015. Transmembrane 6 superfamily member 2 gene variant disentangles nonalcoholic steatohepatitis from cardiovascular disease. Hepatology 61:506-14
269. Sookoian S, Castano GO, Scian R, Mallardi P, Fernandez Gianotti T, et al. 2015. Genetic variation in transmembrane 6 superfamily member 2 and the risk of nonalcoholic fatty liver disease and histological disease severity. Hepatology 61:515-25
270. Wong VW, Vergniol J,Wong GL, Foucher J, Chan HL, et al. 2010. Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease. Hepatology 51:454-62
271. Teratani T, Tomita K, Suzuki T, Oshikawa T, Yokoyama H, et al. 2012. A high-cholesterol diet exacerbates liver fibrosis in mice via accumulation of free cholesterol in hepatic stellate cells. Gastroenterology 142:152-64.e10
272. Mann DA. 2014. Epigenetics in liver disease. Hepatology 60:1418-25
273. Mann J, Chu DC, Maxwell A, Oakley F, Zhu NL, et al. 2010. MeCP2 controls an epigenetic pathway that promotes myofibroblast transdifferentiation and fibrosis. Gastroenterology 138:705-14, 714.e1-4
274. Zeybel M, HardyT,WongYK, Mathers JC, FoxCR, et al. 2012. Multigenerational epigenetic adaptation of the hepatic wound-healing response. Nat. Med. 18:1369-77
275. Murphy SK, Yang H, Moylan CA, Pang H, Dellinger A, et al. 2013. Relationship between methylome and transcriptome in patients with nonalcoholic fatty liver disease. Gastroenterology 145:1076-87
276. Zeybel M, Hardy T, Robinson SM, Fox C, Anstee QM, et al. 2015. Differential DNA methylation of genes involved in fibrosis progression in non-alcoholic fatty liver disease and alcoholic liver disease. Clin. Epigenet. 7:25
277. Esau C, Davis S, Murray SF, Yu XX, Pandey SK, et al. 2006. miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting. Cell Metab. 3:87-98
278. Sekiya M, Yahagi N, Matsuzaka T, Najima Y, Nakakuki M, et al. 2003. Polyunsaturated fatty acids ameliorate hepatic steatosis in obese mice by SREBP-1 suppression. Hepatology 38:1529-39
279. Dentin R, Benhamed F,Pegorier JP, Foufelle F, ViolletB, et al. 2005. Polyunsaturated fatty acids suppress glycolytic and lipogenic genes through the inhibition of ChREBP nuclear protein translocation. J. Clin. Investig. 115:2843-54
280. Parker HM, Johnson NA, Burdon CA, Cohn JS, O'Connor HT, George J. 2012. Omega-3 supplementation and non-alcoholic fatty liver disease: A systematic review and meta-analysis. J. Hepatol. 56:944-51
281. Araya J, Rodrigo R, Videla LA, Thielemann L, Orellana M, et al. 2004. Increase in long-chain polyunsaturated fatty acid n - 6/n - 3 ratio in relation to hepatic steatosis in patients with non-alcoholic fatty liver disease. Clin. Sci. 106:635-43
282. Abid A, Taha O, Nseir W, Farah R, Grosovski M, Assy N. 2009. Soft drink consumption is associated with fatty liver disease independent of metabolic syndrome. J. Hepatol. 51:918-24
283. AbdelmalekMF, Suzuki A, GuyC,Unalp-Arida A, Colvin R, et al. 2010. Increased fructose consumption is associated with fibrosis severity in patients with nonalcoholic fatty liver disease. Hepatology 51:1961-71
284. Bergheim I, Weber S, Vos M, Kramer S, Volynets V, et al. 2008. Antibiotics protect against fructoseinduced hepatic lipid accumulation in mice: role of endotoxin. J. Hepatol. 48:983-92
285. Lee JH, Wada T, Febbraio M, He JH, Matsubara T, et al. 2010. A novel role for the dioxin receptor in fatty acid metabolism and hepatic steatosis. Gastroenterology 139:653-63
286. Peters RL. 1977. Patterns of hepatic morphology in jejunoileal bypass patients.Am. J. Clin.Nutr. 30:53-57
287. Drenick EJ, Fisler J, Johnson D. 1982. Hepatic steatosis after intestinal bypass-prevention and reversal by metronidazole, irrespective of protein-calorie malnutrition. Gastroenterology 82:535-48
288. Wigg AJ, Roberts-Thomson IC, Dymock RB,McCarthy PJ, Grose RH, Cummins AG. 2001. The role of small intestinal bacterial overgrowth, intestinal permeability, endotoxaemia, and tumour necrosis factor αin the pathogenesis of non-alcoholic steatohepatitis. Gut 48:206-11
289. Zietz B, Lock G, Straub RH, Braun B, Scholmerich J, Palitzsch KD. 2000. Small-bowel bacterial overgrowth in diabetic subjects is associated with cardiovascular autonomic neuropathy. Diabetes Care 23:1200-1
290. Ruiz AG, Casafont F, Crespo J, Cayon A, Mayorga M, et al. 2007. Lipopolysaccharide-binding protein plasma levels and liver TNF-alpha gene expression in obese patients: evidence for the potential role of endotoxin in the pathogenesis of non-alcoholic steatohepatitis. Obes. Surg. 17:1374-80
291. Miele L, Valenza V, La Torre G, Montalto M, Cammarota G, et al. 2009. Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. Hepatology 49:1877-87
292. Elinav E, Strowig T, Kau AL, Henao-Mejia J, Thaiss CA, et al. 2011. NLRP6 inflammasome regulates colonic microbial ecology and risk for colitis. Cell 145:745-57
293. Henao-Mejia J, Elinav E, Jin C, Hao L, Mehal WZ, et al. 2012. Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. Nature 482:179-85
294. Turnbaugh PJ, Ley RE, Mahowald MA,Magrini V, Mardis ER, Gordon JI. 2006. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 444:1027-31
295. Backhed F,DingH,Wang T,Hooper LV, Koh GY, et al. 2004. The gut microbiota as an environmental factor that regulates fat storage. PNAS 101:15718-23
296. Backhed F, Manchester JK, Semenkovich CF, Gordon JI. 2007. Mechanisms underlying the resistance to diet-induced obesity in germ-free mice. PNAS 104:979-84
297. Vernia P, Marcheggiano A, Caprilli R, Frieri G, CorraoG, et al. 1995. Short-chain acid topical treatment in distal ulcerative-colitis. Aliment. Pharmacol. Ther. 9:309-13
298. Maslowski KM, Vieira AT, Ng A, Kranich J, Sierro F, et al. 2009. Regulation of inflammatory responses by gut microbiota and chemoattractant receptor GPR43. Nature 461:1282-886
299. Samuel BS, Shaito A, Motoike T, Rey FE, Backhed F, et al. 2008. Effects of the gut microbiota on host adiposity are modulated by the short-chain fatty-acid bindingGprotein-coupled receptor,Gpr41. PNAS 105:16767-72
300. Blumberg H, McCollum EV. 1941. The prevention by choline of liver cirrhosis in rats on high fat, low protein diets. Science 93:598-99
301. Dumas ME, Barton RH, Toye A, Cloarec O, Blancher C, et al. 2006. Metabolic profiling reveals a contribution of gut microbiota to fatty liver phenotype in insulin-resistant mice. PNAS 103:12511-16
302. MouzakiM, Comelli EM, Arendt BM, Bonengel J, Fung SK, et al. 2013. Intestinal microbiota in patients with nonalcoholic fatty liver disease. Hepatology 58:120-27
303. Zhu LX, Baker SS, Gill C, LiuWS, Alkhouri RH, et al. 2013. Characterization of the gutmicrobiomes in non-alcoholic steatohepatitis (NASH) patients: A connection between endogenous alcohol and NASH. Hepatology 57:601-9
304. De Minicis S, Rychlicki C, Agostinelli L, Saccomanno S, Trozzi L, et al. 2014. Dysbiosis contributes to fibrogenesis in the course of chronic liver injury in mice. Hepatology 59:1738-49
305. Dapito DH, Mencin A, Gwak GY, Pradere JP, Jang MK, et al. 2012. Promotion of hepatocellular carcinoma by the intestinal microbiota and TLR4. Cancer Cell 21:504-16